HHS Public Access Author manuscript Author Manuscript
Transl Cancer Res. Author manuscript; available in PMC 2017 May 16. Published in final edited form as: Transl Cancer Res. 2016 November ; 5(Suppl 6): S1142–S1144. doi:10.21037/tcr.2016.11.22.
Cisplatin, Etoposide, and Irinotecan for Relapsed Small-Cell Lung Cancer Angel Qin1 and Gregory P. Kalemkerian1 1Department
of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA
Author Manuscript
Small-cell lung cancer (SCLC) is one of the most chemosensitive solid tumors. Unfortunately, a majority of patients will experience relapse of their disease within one year of completing treatment. Median survival for patients with relapsed disease is dismal at about 5–6 months even with best available therapy. Good performance status and sensitivity to first-line chemotherapy are significant prognostic factors of survival in patients treated for relapsed SCLC (1). Therapy options for relapsed SCLC remain limited, due to poor efficacy of most chemotherapy regimens and the poor performance status of many of these patients at relapse. Currently, topotecan is the only FDA-approved agent for the treatment of relapsed SCLC based on a phase III trial that demonstrated improvement in survival and quality of life compared to best supportive care (2).
Author Manuscript
Goto et al., on behalf of the Japan Clinical Oncology Group, recently published a multicenter phase III trial evaluating combination chemotherapy with cisplatin, etoposide, and irinotecan versus single-agent topotecan for the treatment of patients with relapsed smallcell lung cancer (JCOG0605). Patients with sensitive relapsed SCLC (recurrence or progression of disease at least 90 days after completion of first-line treatment) were randomized in a 1:1 fashion to receive either combination chemotherapy or single-agent topotecan (3). The combination therapy group had improved overall survival (18.2 vs. 12.5 months, p=0.0079) and progression-free survival (5.7 vs. 3.6 months, p
Transl Cancer Res. Author manuscript; available in PMC 2017 May 16. Published in final edited form as: Transl Cancer Res. 2016 November ; 5(Suppl 6): S1142–S1144. doi:10.21037/tcr.2016.11.22.
Cisplatin, Etoposide, and Irinotecan for Relapsed Small-Cell Lung Cancer Angel Qin1 and Gregory P. Kalemkerian1 1Department
of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA
Author Manuscript
Small-cell lung cancer (SCLC) is one of the most chemosensitive solid tumors. Unfortunately, a majority of patients will experience relapse of their disease within one year of completing treatment. Median survival for patients with relapsed disease is dismal at about 5–6 months even with best available therapy. Good performance status and sensitivity to first-line chemotherapy are significant prognostic factors of survival in patients treated for relapsed SCLC (1). Therapy options for relapsed SCLC remain limited, due to poor efficacy of most chemotherapy regimens and the poor performance status of many of these patients at relapse. Currently, topotecan is the only FDA-approved agent for the treatment of relapsed SCLC based on a phase III trial that demonstrated improvement in survival and quality of life compared to best supportive care (2).
Author Manuscript
Goto et al., on behalf of the Japan Clinical Oncology Group, recently published a multicenter phase III trial evaluating combination chemotherapy with cisplatin, etoposide, and irinotecan versus single-agent topotecan for the treatment of patients with relapsed smallcell lung cancer (JCOG0605). Patients with sensitive relapsed SCLC (recurrence or progression of disease at least 90 days after completion of first-line treatment) were randomized in a 1:1 fashion to receive either combination chemotherapy or single-agent topotecan (3). The combination therapy group had improved overall survival (18.2 vs. 12.5 months, p=0.0079) and progression-free survival (5.7 vs. 3.6 months, p
